Aaron Shawn D
Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
Paediatr Respir Rev. 2007 Sep;8(3):256-61. doi: 10.1016/j.prrv.2007.04.005. Epub 2007 Jun 6.
Patients with cystic fibrosis (CF) suffer from chronic bacterial infection of the airways, and many patients are infected with multiresistant bacteria. Combination antibiotic susceptibility tests, or antibiotic synergy tests, are in vitro tests that have been developed to allow clinicians to choose combinations of antibiotics that should be more effective at killing, or inhibiting, multiresistant bacterial pathogens. Only one randomised controlled clinical trial has been performed to determine whether combination antibiotic susceptibility testing leads to an improved clinical outcome for patients with acute pulmonary exacerbations of CF. The results of this clinical trial were disappointing - treatment based on combination antibiotic susceptibility testing was no more effective than treatment based on conventional culture and sensitivity testing. The adoption of antibiotic synergy testing as routine practice for patients with CF would be costly and would not be justified as there is insufficient evidence to suggest that the routine use of these tests improves clinical outcomes.
囊性纤维化（CF）患者会遭受气道的慢性细菌感染，许多患者感染的是多重耐药菌。联合抗生素敏感性试验，即抗生素协同试验，是体外试验，其开发目的是让临床医生能够选择对多重耐药细菌病原体更有效地杀灭或抑制的抗生素组合。仅进行过一项随机对照临床试验来确定联合抗生素敏感性试验是否能改善CF急性肺部加重患者的临床结局。该临床试验的结果令人失望——基于联合抗生素敏感性试验的治疗并不比基于传统培养和药敏试验的治疗更有效。将抗生素协同试验作为CF患者的常规做法成本高昂，而且没有依据，因为没有足够证据表明常规使用这些试验能改善临床结局。
